Biological Products; General records and postmarket adverse experience reporting
No material or nonsubstantive change to a currently approved collection
No
Regular
Approved without change
03/24/2023
03/20/2023
Approved with the understanding that FDA will now discontinue 0910-0834, given that the associated burden is now reflected in this package.
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
04/30/2024
04/30/2024
04/30/2024
715,688
0
715,490
5,914,444
0
5,914,355
0
0
0
This information collection supports Food and Drug Administration (FDA) regulations regarding certain general requirements and postmarket adverse experience reporting for biological products. Respondents to the collection are manufacturers of these products subject to the applicable regulations. The information collection enables FDA to implement public health protection provisions of the Federal Food, Drug, and Cosmetic Act.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.